DEA Grants Pharmaceutical Company Monopoly on Medical CBD
(ANTIMEDIA) — News circulated recently that the DEA had rescheduled cannabidiol (CBD), the nonpsychoactive ingredient in cannabis, but the technicalities of the agency’s decision actually show their ruling is highly restrictive. The decision concerned a recently FDA-approved pharmaceutical version of CBD, produced by GW Pharmaceuticals. Due to the federal government’s continued prohibition of cannabis Epidiolex was prohibited from going to market unless […]
The article, "DEA Grants Pharmaceutical Company Monopoly on Medical CBD", was syndicated from and first appeared at: http://theantimedia.com/dea-pharmaceutical-monopoly-medical-cbd/.
You may find more great articles by Carey Wedler on http://theantimedia.org/.